Alnylam & Roche Launch Global Phase III Study to Reduce Hypertension Risks
Alnylam and Roche have initiated a global Phase III study, Zenith, aiming to decrease severe cardiovascular risks in patients with uncontrolled hypertension. The first patient has been dosed, triggering a $300 million milestone payment from Roche to Alnylam.
The Zenith study will assess Alnylam's product candidate, Zilebesiran, administered subcutaneously to patients twice a year. This global entry trial involves around 11,000 patients across 35 countries. The study's goal is to reduce the risk of severe cardiovascular events in patients with uncontrolled hypertension. Roche licensed the product candidate from Alnylam, and the treatment of the first patient under this agreement has triggered a $300 million milestone payment.
The Zenith Phase III study, a collaboration between Alnylam and Roche, has begun. The first patient has been dosed, leading to a $300 million payment from Roche to Alnylam. This global entry trial aims to demonstrate the potential of Zilebesiran in reducing cardiovascular risks in patients with uncontrolled hypertension.
